Concourse Financial Group Securities, Inc. Xtl Biopharmaceuticals LTD Transaction History
Concourse Financial Group Securities, Inc.
- $0
- Q2 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
100.0%
Previous 100.0%
Shares
29 transactions
Others Institutions Holding XTLB
# of Institutions
6Shares Held
427KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$232,6980.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$232,6980.04% of portfolio
-
Rhumbline Advisers Boston, MA17.3KShares$20,1950.0% of portfolio
-
Morgan Stanley New York, NY11KShares$12,8820.0% of portfolio
-
Ubs Group Ag1.34KShares$1,5630.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $6.38M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...